Why the study?
Does pioglitazone plus metformin improve biomarkers of inflammation and platelet activation compared to glimepiride plus metformin in patients with T2DM and dyslipidemia?
Does pioglitazone plus metformin improve biomarkers of inflammation and platelet activation compared to glimepiride plus metformin in patients with T2DM and dyslipidemia?
The fixed combination of pioglitazone and metformin improves surrogate markers of platelet function and chronic systemic inflammation in patients with type 2 diabetes compared to glimepiride and metformin.
No takes yet. Share an insight, caveat, or question.
Supports pioglitazone-metformin over glimepiride-metformin to lower inflammatory and platelet biomarkers in T2DM with dyslipidemia; extends pleiotropic RCT evidence.
Schöndorf et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: